CryoPort (CYRX) Achieves ISO Certification for Enhanced Cell Therapy Transport Standards

Cryoport Achieves Groundbreaking ISO Certification for Cell Therapy Transport

Cryoport, Inc. (NASDAQ: CYRX), a frontrunner in temperature-controlled supply chain solutions for the life sciences, proudly announces its achievement of the ISO 21973:2020 certification through its Cryoport Systems division. This landmark certification marks a pivotal advancement in the global supply chain solutions market, as it establishes stringent standards for the transport of human cells utilized in therapeutic applications. With the cell and gene therapy industry experiencing rapid growth, ensuring the highest levels of safety, traceability, and integrity in the transportation of these critical biological materials becomes essential for patient outcomes.

The ISO 21973 standard, developed with contributions from Cryoport Systems since its inception in 2020, provides comprehensive guidelines that cover environmental control, logistics management, and the processes necessary for transporting therapeutic cells. Given that any deviation in these processes could significantly affect patient health, adherence to this standard is crucial. Cryoport has long maintained its proprietary Chain of Compliance®, which aligns with these rigorous guidelines, thereby reinforcing its commitment to minimizing risks associated with temperature excursions and contamination during transit.

Jerrell Shelton, Chairman & CEO of Cryoport, underscores the significance of this certification in enhancing the company’s leadership position within the life sciences sector. He points out that this achievement not only showcases Cryoport's dedication to excellence but also follows their recognition with the 2025 CPHI Award for Supply Chain Excellence. The flexibility of the ISO 21973 standard extends beyond regenerative medicine, as it can be applied to other areas within the life sciences, including reproductive medicine and animal health, thus broadening its impact and relevance across the industry.

In addition to this prestigious certification, Cryoport is actively providing resources for industry stakeholders to better understand the implications of the ISO 21973 standard. Interested parties can visit Cryoport’s website or download their whitepaper to gain insights into how these guidelines can enhance supply chain efficacy in regenerative medicine. The company’s commitment to advancing safety and compliance in the transportation of therapeutic cells positions it as a pivotal player in the evolving landscape of life sciences logistics.

With the acquisition of the ISO 21973:2020 certification, Cryoport not only solidifies its role as an industry leader but also sets a new benchmark for quality and safety in the transportation of life-saving therapies. This milestone is expected to catalyze further innovations and improvements in the field, ultimately benefiting patients and healthcare providers alike.